O Shaughnessy Asset Management LLC Acquires 2,864 Shares of Becton, Dickinson and Company (NYSE:BDX)

O Shaughnessy Asset Management LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 28.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,002 shares of the medical instruments supplier's stock after acquiring an additional 2,864 shares during the period. O Shaughnessy Asset Management LLC's holdings in Becton, Dickinson and Company were worth $2,950,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wesbanco Bank Inc. boosted its stake in Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier's stock worth $580,000 after purchasing an additional 48 shares in the last quarter. S.A. Mason LLC lifted its position in Becton, Dickinson and Company by 3.7% during the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier's stock worth $321,000 after buying an additional 50 shares in the last quarter. Hillsdale Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 1.7% during the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock worth $694,000 after acquiring an additional 50 shares during the last quarter. Americana Partners LLC raised its stake in shares of Becton, Dickinson and Company by 3.5% in the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock worth $345,000 after acquiring an additional 52 shares during the last quarter. Finally, Picton Mahoney Asset Management lifted its position in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity

In related news, EVP David Shan sold 500 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Richard Byrd sold 459 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now directly owns 6,952 shares of the company's stock, valued at approximately $1,598,960. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,196 shares of company stock worth $962,685 in the last 90 days. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Up 1.9 %

Shares of Becton, Dickinson and Company stock traded up $3.91 during trading on Tuesday, reaching $208.99. 646,753 shares of the company were exchanged, compared to its average volume of 2,100,080. Becton, Dickinson and Company has a twelve month low of $199.37 and a twelve month high of $251.99. The business has a 50-day moving average price of $229.19 and a 200-day moving average price of $231.12. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $60.01 billion, a price-to-earnings ratio of 34.73, a P/E/G ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a share repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.99%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.

Analyst Ratings Changes

A number of analysts recently weighed in on BDX shares. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a report on Tuesday, January 28th. Barclays lowered their target price on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a research note on Monday. Finally, StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of "Buy" and a consensus price target of $275.71.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.